Halyard Health (HYH) Earning Somewhat Favorable Media Coverage, Report Finds

Media headlines about Halyard Health (NYSE:HYH) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Halyard Health earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 45.9248491208222 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of research analysts have commented on HYH shares. Zacks Investment Research upgraded Halyard Health from a “sell” rating to a “hold” rating in a research note on Thursday, October 19th. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. TheStreet cut Halyard Health from a “b-” rating to a “c+” rating in a research note on Monday, October 30th. KeyCorp restated a “hold” rating on shares of Halyard Health in a research note on Tuesday, October 17th. Finally, Stifel Nicolaus restated a “buy” rating and set a $52.00 price objective on shares of Halyard Health in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $49.00.

Halyard Health (NYSE:HYH) opened at $47.57 on Thursday. The company has a quick ratio of 1.19, a current ratio of 2.13 and a debt-to-equity ratio of 0.49. Halyard Health has a one year low of $35.24 and a one year high of $50.99. The company has a market capitalization of $2,250.00, a PE ratio of 39.97, a P/E/G ratio of 2.50 and a beta of 1.76.

Halyard Health (NYSE:HYH) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The business had revenue of $401.40 million for the quarter, compared to analysts’ expectations of $394.54 million. During the same quarter in the previous year, the firm posted $0.48 earnings per share. The company’s revenue was up 1.0% compared to the same quarter last year. analysts forecast that Halyard Health will post 2.08 EPS for the current year.

WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2018/01/25/halyard-health-hyh-earning-somewhat-favorable-media-coverage-report-finds.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply